Clinical Trials in Australia

For non-cf bronchiectasis patients with NTM lung infections is to be conducted in Australia
Insmed Incorporated is recruiting patients diagnosed with Nontuberculous Mycobacterial (NTM) lung infection that is caused by Mycobacterium avium complex (MAC) to enroll in a Phase 3 study. The purpose of the study is to test the efficacy and safety of a medication that has not been approved for use in the treatment of NTM called Liposomal Amikacin for Inhalation (LAI), given once a day using a nebulizer in patients with lung infection due to MAC that has not previously been successfully treated.

LAI will be administered in addition to standard therapy with other medications against lung infection called multi-drug therapy. The study is being conducted to learn the effects (good and bad) of the study drug LAI on you and your lung infection, test what the body does to the study drug, LAI and see if LAI improves your quality of life.

Patients must be 18 years of age or older at screening, and fulfill other eligibility criteria, including the willingness to stay on all of the prescribed medications for the duration of the study. Click on Eligibility and Study Locations to learn more

Alternatively you may email  for more information.

We urge you to consider taking part in this clinical trial. Amikacin is a big step forward and could make a major contribution to many people living with NTM.

But remember to discuss  with your Doctor first, whether this trial is for you

Donations for NTM research can be made at the Gallipoli Research Foundation:

To search for all Clinical Trials being conducted in Australia click Australian New Zealand Clinical Trials Register

To learn how to search the Registry click Search Registry